24 May 2013
Keywords: scotland, pfizer, sutent, scottish, medicines, consortium, ruled
Article | 30 October 2006
The Scottish Medicines Consortium has ruled against the funding of Pfizer's new cancer drug Sutent (sunitinib), for the second-line
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 October 2006
23 May 2013
© 2013 thepharmaletter.com